Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020–2022): A retrospective longitudinal SARS-CoV-2 serological surveillance

References

• World Health Organization. Coronavirus (COVID-19) dashboard. [accessed 2023 Aug 7]. https://covid19.who.int/.
   Google Scholar
• Centers for Disease Control and Prevention. COVID-19. [accessed 2023 Aug 7]. https://www.cdc.gov/coronavirus/2019-nCoV/index.html.
   Google Scholar
• Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81(4):495–8. doi:10.1007/s40265-021-01480-7. PMID: 33683637.
   PubMed Web of Science ®Google Scholar
• Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, et al. Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–50. doi:10.1056/NEJMoa2107456. PMID: 34043894.
   PubMed Web of Science ®Google Scholar
• BNT162b2 vaccine for prevention of COVID-19. Aust Prescr. 2021;44(1):57–8. doi:10.18773/austprescr.2021.008. PMID: 33911334.
   PubMedGoogle Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. doi:10.1056/NEJMoa2034577. PMID: 33301246.
   PubMed Web of Science ®Google Scholar
• Marcotte H, Piralla A, Zuo F, Du L, Cassaniti I, Wan H, Kumagai-Braesh M, Andréll J, Percivalle E, Sammartino JC, et al. Immunity to SARS-CoV-2 up to 15 months after infection. iScience. 2022;25(2):103743. doi:10.1016/j.isci.2022.103743. PMID: 35018336.
   PubMed Web of Science ®Google Scholar
• Zhang S, Xu K, Li C, Zhou L, Kong X, Peng J, Zhu F, Bao C, Jin H, Gao Q, et al. Long-term kinetics of SARS-CoV-2 antibodies and impact of inactivated vaccine on SARS-CoV-2 antibodies based on a COVID-19 patients cohort. Front Immunol. 2022;13:829665. doi:10.3389/fimmu.2022.829665. PMID: 35154152.
   PubMed Web of Science ®Google Scholar
• Valleriani F, Mancuso E, Vincifori G, Teodori L, Di Marcantonio L, Spedicato M, Leone A, Savini G, Morelli D, Bonfini B, et al. Neutralization of SARS-CoV-2 variants by serum from BNT162b2 vaccine recipients. Viruses. 2021;13(10):2011. doi:10.3390/v13102011. PMID: 34696441.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Polack FP, Zerbini C, et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761–73. doi:10.1056/NEJMoa2110345. PMID: 34525277.
   PubMed Web of Science ®Google Scholar
• Tychala A, Meletis G, Katsimpourlia E, Gkeka I, Dimitriadou R, Sidiropoulou E, Skoura L. Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response. Hum Vaccin Immunother. 2021;17:5148–9. doi:10.1080/21645515.2021.1991710. PMID: 34714711.
   PubMed Web of Science ®Google Scholar
• Firinu D, Perra A, Campagna M, Littera R, Fenu G, Meloni F, Cipri S, Sedda F, Conti M, Miglianti M, et al. Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination. Clin Exp Med. 2022;22(3):477–85. doi:10.1007/s10238-021-00771-3. PMID: 34741188.
   PubMed Web of Science ®Google Scholar
• Wei J, Pouwels KB, Stoesser N, Matthews PC, Diamond I, Studley R, Rourke E, Cook D, Bell JI, Newton JN, et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med. 2022;28(5):1072–82. doi:10.1038/s41591-022-01721-6. PMID: 35165453.
   PubMed Web of Science ®Google Scholar
• Bouwmans P, Messchendorp AL, Sanders JS, Hilbrands L, Reinders MEJ, Vart P, Bemelman FJ, Abrahams AC, van den Dorpel MA, Ten Dam MA, et al. Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study. BMC Nephrol. 2022;23(1):55. doi:10.1186/s12882-022-02680-3. PMID: 35123437.
   PubMed Web of Science ®Google Scholar
• Frey S, Chiang TP, Connolly CM, Teles M, Alejo JL, Boyarsky BJ, Christopher-Stine L, Werbel WA, Massie AB, Segev DL, et al. Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease. Lancet Rheumatol. 2022;4(4):e241–e3. doi:10.1016/S2665-9913(21)00417-3. PMID: 35072108.
   PubMedGoogle Scholar
• Macías J, Fernández-Fuertes M, Oliver N, Corma-Gómez A, Real LM, Pineda JA. Lower probability of persistence of total anti-SARS-CoV-2 antibodies after COVID-19 among people living with HIV. Clin Microbiol Infect. 2022;28:755–6. doi:10.1016/j.cmi.2022.01.028. PMID: 35150883.
   PubMed Web of Science ®Google Scholar
• Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, San JE, Cromer D, Scheepers C, Amoak DG, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602(7898):654–6. doi:10.1038/s41586-021-04387-1. PMID: 35016196.
   PubMed Web of Science ®Google Scholar
• Yu J, Collier AY, Rowe M, Mardas F, Ventura JD, Wan H, Miller J, Powers O, Chung B, Siamatu M, et al. Comparable neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 variants. medRxiv. 2022 (in press). doi:10.1101/2022.02.06.22270533. PMID: 35169817.
   Google Scholar
• Cheng SS, Mok CK, Li JK, Ng SS, Lam BH, Jeevan T, Kandeil A, Pekosz A, Chan KC, Tsang LC, et al. Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection. J Clin Virol. 2022;156:105273. doi:10.1016/j.jcv.2022.105273. PMID: 36081282.
   PubMed Web of Science ®Google Scholar
• Istituto Superiore di Sanità; Epicentro - Epidemiology for Public Health. National COVID-19 vaccination plan. [accessed 2023 Mar 26]. https://www.epicentro.iss.it/en/vaccines/covid-19-vaccination-plan.
   Google Scholar
• Agenzia Italiana del Farmaco. Comirnaty-BioNTech/Pfizer. [accessed 26 Mar 2023]. https://www.aifa.gov.it/comirnaty.
   Google Scholar
• Domnich A, De Pace V, Pennati BM, Caligiuri P, Varesano S, Bruzzone B, Orsi A. Evaluation of extraction-free RT-qPCR methods for SARS-CoV-2 diagnostics. Arch Virol. 2021;166(10):2825–8. doi:10.1007/s00705-021-05165-0. PMID: 34302551.
   PubMed Web of Science ®Google Scholar
• Ponticelli D, Madotto F, Conti S, Antonazzo IC, Vitale A, Della Ragione G, Romano ML, Borrelli M, Schiavone B, Polosa R, et al. Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up. Intern Emerg Med. 2022;17(2):481–6. doi:10.1007/s11739-021-02857-y. PMID: 34637084.
   PubMed Web of Science ®Google Scholar
• Jalkanen P, Kolehmainen P, Haveri A, Huttunen M, Laine L, Österlund P, Tähtinen PA, Ivaska L, Maljanen S, Reinholm A, et al. Vaccine-induced antibody responses against SARS-CoV-2 variants-of-concern six months after the BNT162b2 COVID-19 mRNA vaccination. Microbiol Spectr. 2022;10(2):e0225221. doi:10.1128/spectrum.02252-21. PMID: 35262410.
   PubMed Web of Science ®Google Scholar
• Olariu TR, Ursoniu S, Marincu I, Lupu MA. Dynamics of antibody response to BNT162b2 mRNA COVID-19 vaccine: a 7-month follow-up study. Medicina (Kaunas). 2021;57(12):1330. doi:10.3390/medicina57121330. PMID: X.
   PubMed Web of Science ®Google Scholar
• Infantino M, Manfredi M, Stacchini L, Cosma C, Grossi V, Lari B, Russo E, Amedei A, Benucci M, Veneziani F, et al. The role of neutralizing antibodies by sVNT after two doses of BNT162b2 mRNA vaccine in a cohort of Italian healthcare workers. Clin Chem Lab Med. 2022;60(6):934–40. doi:10.3390/medicina57121330. PMID: 34946275.
   PubMed Web of Science ®Google Scholar
• Coppeta L, Ferrari C, Somma G, Mazza A, D’Ancona U, Marcuccilli F, Grelli S, Aurilio MT, Pietroiusti A, Magrini A, et al. Reduced titers of circulating anti-SARS-CoV-2 antibodies and risk of COVID-19 infection in healthcare workers during the nine months after immunization with the BNT162b2 mRNA vaccine. Vaccines (Basel). 2022;10(2):141. doi:10.3390/vaccines10020141. PMID: 35214600.
   PubMed Web of Science ®Google Scholar
• Cocomazzi G, Piazzolla V, Squillante MM, Antinucci S, Giambra V, Giuliani F, Maiorana A, Serra N, Mangia A. Early serological response to BNT162b2 mRNA vaccine in healthcare workers. Vaccines (Basel). 2021;9(8):913. doi:10.3390/vaccines10020141. PMID: 35214600.
   PubMed Web of Science ®Google Scholar
• Bonnet B, Chabrolles H, Archimbaud C, Brebion A, Cosme J, Dutheil F, Lambert C, Junda M, Mirand A, Ollier A, et al. Decline of humoral and cellular immune responses against SARS-CoV-2 6 months after full BNT162b2 vaccination in hospital healthcare workers. Front Immunol. 2022;13:842912. doi:10.3389/fimmu.2022.842912. PMID: 35309363.
   PubMedGoogle Scholar
• Stellini R, Gianello R, Gomarasca W. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed? Infection. 2022;50(6):1573–7. doi:10.1007/s15010-022-01816-9. PMID: 35391649.
   PubMed Web of Science ®Google Scholar
• Isgrò MA, Trillò G, Russo L, Tornesello AL, Buonaguro L, Tornesello ML, Miscio L, Normanno N, Bianchi AAM, Buonaguro FM, et al. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT – IRCCS “Fondazione Pascale” cancer center (Naples, Italy). Infect Agent Cancer. 2022;17(1):40. doi:10.1186/s13027-022-00451-1. PMID: 35902961.
   PubMed Web of Science ®Google Scholar
• Hussein K, Dabaja-Younis H, Szwarcwort-Cohen M, Almog R, Leiba R, Weissman A, Mekel M, Hyams G, Horowitz NA, Gepstein V, et al. Third BNT162b2 vaccine booster dose against SARS-CoV-2-induced antibody response among healthcare workers. Vaccines (Basel). 2022;10(10):1741. doi:10.3390/vaccines10101741. PMID: 36298606.
   PubMed Web of Science ®Google Scholar
• Redjoul R, Le Bouter A, Beckerich F, Fourati S, Maury S. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. Lancet. 2021;398(10297):298–9. doi:10.1016/S0140-6736(21)01594-4. PMID: 34270933.
   PubMed Web of Science ®Google Scholar
• Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661–2. doi:10.1056/NEJMc2108861. PMID: 34161700.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Frenck RW Jr, Walsh EE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Bailey R, Swanson KA, Xu X, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. N Engl J Med. 2021;385(17):1627–9. doi:10.1056/NEJMc2113468. PMID: 34525276.
   PubMed Web of Science ®Google Scholar
• Desmecht S, Tashkeev A, El Moussaoui M, Marechal N, Perée H, Tokunaga Y, Fombellida-Lopez C, Polese B, Legrand C, Wéry M, et al. Kinetics and persistence of the cellular and humoral immune responses to BNT162b2 mRNA vaccine in SARS-CoV-2-naive and -experienced subjects: impact of booster dose and breakthrough infections. Front Immunol. 2022;13:863554. doi:10.3389/fimmu.2022.863554. PMID: 35711445.
   PubMed Web of Science ®Google Scholar
• Pani A, Cento V, Vismara C, Campisi D, Di Ruscio F, Romandini A, Senatore M, Schenardi PA, Gagliardi OM, Giroldi S, et al. Results of the RENAISSANCE study: REsponse to BNT162b2 COVID-19 vacciNe—short- and long-term immune reSponse evAluation in health care workErs. Mayo Clinic Proc. 2021;96(12):2966–79. doi:10.1016/j.mayocp.2021.08.013. PMID: 34736776.
   PubMed Web of Science ®Google Scholar
• Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, Olsho LEW, Caban-Martinez AJ, Fowlkes AL, Lutrick K, et al. Prevention and attenuation of covid-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021;385(4):320–9. doi:10.1056/NEJMoa2107058. PMID: 34192428.
   PubMed Web of Science ®Google Scholar
• Della Valle P, Fabbri M, Madotto F, Ferrara P, Cozzolino P, Calabretto E, D’Orso MI, Longhi E, Polosa R, Riva MA, et al. Occupational exposure in the Lombardy Region (Italy) to SARS-CoV-2 infection: results from the MUSTANG–OCCUPATION–COVID-19 study. Int J Environ Res Public Health. 2021;18(5):2567. doi:10.3390/ijerph18052567. PMID: 33806578.
   PubMed Web of Science ®Google Scholar
• De Pace V, Bruzzone B, Orsi A, Ricucci V, Domnich A, Guarona G, Randazzo N, Stefanelli F, Battolla E, Dusi PA, et al. Comparative analysis of five multiplex RT-PCR assays in the screening of SARS-CoV-2 variants. Microorganisms. 2022;10(2):306. doi:10.3390/microorganisms10020306. PMID: 35208761.
   PubMed Web of Science ®Google Scholar
• Ricucci V, De Pace V, Domnich A, Orsi A, Icardi G, Bruzzone B. Fast and presumptive diagnosis of SARS-CoV-2 Omicron variants vs Delta. BJSTR. 2022;42(3). doi:10.26717/BJSTR.2022.42.006793. PMID: Not applicable.
   Google Scholar
• Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C, Kreiss Y, Alroy-Preis S, Regev-Yochay G, Mendelson E, et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N Engl J Med. 2022;386(5):492–4. doi:10.1056/NEJMc2119358. PMID: 34965337.
   PubMed Web of Science ®Google Scholar
• Abu Jabal K, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, Edelstein M. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;26(6):210009. doi:10.2807/1560-7917.ES.2021.26.6.2100096. PMID: 33573712.
   Google Scholar